SCHEMBL3317629

SCHEMBL3317629

CC(=O)N[C@@H](CSc1ccccc1)C(=O)O

nearest known ligand 0.69

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
MTNR1A P48039 7/20 0.69
MTNR1B P49286 7/20 0.69
PAM P19021 1/20 0.49
PRNP P04156 1/20 0.48
NPSR1 Q6W5P4 1/20 0.48
RXFP1 Q9HBX9 1/20 0.48
FFAR1 O14842 1/20 0.47
MMP13 P45452 2/20 0.46
KDM4E B2RXH2 1/20 0.46
MAPT P10636 1/20 0.46
THRB P10828 1/20 0.46
ALOX15 P16050 1/20 0.46
NFKB1 P19838 1/20 0.46
PTGS2 P35354 1/20 0.46
THPO P40225 1/20 0.46
RECQL P46063 1/20 0.46
BLM P54132 1/20 0.46
SMN1; SMN2 Q16637 1/20 0.46
ALDH1A1 P00352 1/20 0.44
MAOA P21397 1/20 0.44

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL4542367 1.00 MTNR1A (0.69) MTNR1AMTNR1BPAMPRNPNPSR1
SCHEMBL11552778 0.89 MTNR1A (0.54) MTNR1AMTNR1BPAMPRNPNPSR1
SCHEMBL10976954 0.86 MTNR1A (0.63) MTNR1AMTNR1BPAMRXFP1MMP13
SCHEMBL10976956 0.86 MTNR1A (0.63) MTNR1AMTNR1BPAMRXFP1MMP13
SCHEMBL1158188 0.86 PRNP (0.57) MTNR1AMTNR1BPRNPNPSR1RXFP1
SCHEMBL7290207 0.85 MTNR1A (0.51) MTNR1AMTNR1BPAMPRNPNPSR1
SCHEMBL7924179 0.84 MTNR1A (0.53) MTNR1AMTNR1BFFAR1KDM4EMAPT
SCHEMBL11004997 0.83 PRNP (0.51) MTNR1AMTNR1BPAMPRNPNPSR1
SCHEMBL11004988 0.83 PRNP (0.51) MTNR1AMTNR1BPAMPRNPNPSR1
SCHEMBL28910863 0.81 ACE (0.49) MTNR1AMTNR1BPRNPNPSR1RXFP1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 421 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
CN-122011401-A Photo-responsive brush-shaped macromolecular emulsifier and preparation method thereof 奇瑞汽车股份有限公司 2026-05-12 CN claimed
US-20260062367-A1 EVOLVING RANDOM HETEROPOLYMERS TOWARDS CATALYTICALLY ACTIVE MATERIALS MASSACHUSETTS INST TECHNOLOGY (US) 2026-03-05 US claimed
EP-4662099-A1 APPARATUS FOR SECURING AT LEAST ONE SENSOR DEVICE TO A RAIL OF A RAILWAY TRACK INSTALLATION Siemens Mobility GmbH (DE) 2025-12-17 EP claimed
EP-4084830-B1 BIOACTIVE PLASTICS WITH PROGRAMMABLE DEGRADATION AND MICROPLASTIC ELIMINATION UNIV CALIFORNIA (US) 2025-12-10 EP claimed
US-12454501-B2 Evolving random heteropolymers towards catalytically active materials MASSACHUSETTS INSTITUTE OF TECHNOLOGY (US) 2025-10-28 US claimed
CN-120137239-A Preparation method of plaque display type caries preventing invisible appliance based on iron-based nano enzyme catalysis and traditional Chinese medicine caries inhibition synergy 中国医科大学附属口腔医院 2025-06-13 CN claimed
CN-119324890-B SPMA protocol design method based on BiLSTM channel load prediction 北京理工大学 2025-04-18 CN claimed
WO-2024123469-A9 EVOLVING RANDOM HETEROPOLYMERS TOWARDS CATALYTICALLY ACTIVE MATERIALS MASSACHUSETTS INSTITUTE OF TECHNOLOGY (US) 2025-04-17 WO claimed
CN-119715877-A Method for detecting cigarette smoke exposure biomarker based on nanofiber solid phase extraction 东南大学 2025-03-28 CN claimed
CN-119449599-A ADS-B information transmission system network design method based on ad hoc network technology 四川九洲空管科技有限责任公司 2025-02-14 CN claimed
CN-111830181-A Fresh chilled meat freshness marker and screening and prediction model fitting method and application thereof 扬州大学 2020-10-27 CN claimed
US-20190346449-A1 BTEX METABOLITES DERIVATIZATION KIT AND COMPOSITION BOARD OF REGENTS, THE UNIVERSITY OF TEXAS SYSTEM 2019-11-14 US claimed
EP-2976061-B1 COMBINATIONS OF N-ACETYL CYSTEINE DERIVATIVES AND CRANBERRY POLYPHENOLS IN COMPOSITIONS AND METHODS FOR PREVENTING AND TREATING PERIODONTAL DISEASES AND PERI-IMPLATITIS DENTALMED PHARM HOLDING LTD (BE) 2019-10-16 EP claimed
WO-2017214549-A1 BTEX METABOLITES DERIVATIZATION KIT AND COMPOSITION BOARD OF REGENTS THE UNIVERSITY OF TEXAS SYSTEM (US) 2017-12-14 WO claimed
US-20170219570-A1 Compositions, Apparatus and Methods for Monitoring Biomarkers Berkeley Test, LLC 2017-08-03 US claimed
EP-2976061-A1 COMBINATIONS OF N-ACETYL CYSTEINE DERIVATIVES AND CRANBERRY POLYPHENOLS IN COMPOSITIONS AND METHODS FOR PREVENTING AND TREATING PERIODONTAL DISEASES AND PERI-IMPLATITIS Dentalmed Pharm Holding Ltd. (BE) 2016-01-27 EP claimed
EP-2893346-A2 COMPOSITIONS, APPARATUS AND METHODS FOR MONITORING BIOMARKERS Berkeley Test LLC (US) 2015-07-15 EP claimed
WO-2014147613-A1 COMBINATIONS OF N-ACETYL CYSTEINE DERIVATIVES AND CRANBERRY POLYPHENOLS IN COMPOSITIONS AND METHODS FOR PREVENTING AND TREATING PERIODONTAL DISEASES AND PERI-IMPLATITIS DENTALMED PHARM HOLDING LTD. (BE) 2014-09-25 WO claimed
WO-2014039794-A2 COMPOSITIONS, APPARATUS AND METHODS FOR MONITORING BIOMARKERS Berkeley Test, LLC (US) 2014-03-13 WO claimed
US-20140065606-A1 Compositions, Apparatus and Methods for Monitoring Biomarkers Berkeley Test, LLC (US) 2014-03-06 US claimed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20260062367-A1 EVOLVING RANDOM HETEROPOLYMERS TOWARDS CATALYTICALLY ACTIVE MATERIALS ESD, TET2, HPD MTNR1A 2914/4885MTNR1B 3888/4885PAM 580/4885
US-12454501-B2 Evolving random heteropolymers towards catalytically active materials PNKP, MGAM, HMBS MTNR1A 4221/4885MTNR1B 4438/4885PAM 1559/4885
US-20190346449-A1 BTEX METABOLITES DERIVATIZATION KIT AND COMPOSITION BTD, BTF3, PTMS MTNR1A 1582/4885MTNR1B 2110/4885PAM 1030/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.